Literature DB >> 2483111

Open channel block of NMDA receptor responses evoked by tricyclic antidepressants.

E Sernagor1, D Kuhn, L Vyklicky, M L Mayer.   

Abstract

The action of desipramine (DMI) and promazine on the response of mouse hippocampal neurons to the excitatory amino acid N-methyl-D-aspartic acid (NMDA) was investigated using whole-cell and single-channel recording. DMI at 20-50 microM was a potent, selective antagonist of responses to NMDA but not kainate or quisqualate. At -60 mV, the Kd for DMI block of responses to NMDA was 10 microM. The potency of DMI as an NMDA antagonist was highly voltage-dependent and behaved as though the Kd increased e-fold per 36 mV depolarization, reflecting an increase in the dissociation rate constant. Prior block of NMDA receptors with Mg2+ prevented binding of DMI, suggesting an action in the open channel. Single-channel analysis showed a decrease in the open time and burst length distributions, consistent with binding of DMI to open channels. We suggest that the action of DMI on NMDA receptor channels is similar to that of MK-801 and does not reflect binding to other domains, such as the regulatory sites for Zn2+ and glycine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2483111     DOI: 10.1016/0896-6273(89)90306-1

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  25 in total

Review 1.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

2.  Structure-activity analysis of binding kinetics for NMDA receptor competitive antagonists: the influence of conformational restriction.

Authors:  M Benveniste; M L Mayer
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

3.  Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations.

Authors:  Andrea G Ludolph; Patrick T Udvardi; Ulrike Schaz; Carolin Henes; Oliver Adolph; Henry U Weigt; Joerg M Fegert; Tobias M Boeckers; Karl J Föhr
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

4.  Antidepressants that inhibit both serotonin and norepinephrine reuptake impair long-term potentiation in hippocampus.

Authors:  Jennifer D Cooke; Hannah M Cavender; Hope K Lima; Lawrence M Grover
Journal:  Psychopharmacology (Berl)       Date:  2014-04-30       Impact factor: 4.530

5.  Selective reduction of N-methyl-D-aspartate-evoked responses by 1,3-di(2-tolyl)guanidine in mouse and rat cultured hippocampal pyramidal neurones.

Authors:  E J Fletcher; J Church; K Abdel-Hamid; J F MacDonald
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

6.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

Review 7.  Ketamine and the next generation of antidepressants with a rapid onset of action.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy Diazgranados; Carlos A Zarate
Journal:  Pharmacol Ther       Date:  2009-05-03       Impact factor: 12.310

8.  Alpha 4-2 beta 2 and other nicotinic acetylcholine receptor subtypes as targets of psychoactive and addictive drugs.

Authors:  J Connolly; J Boulter; S F Heinemann
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

Review 9.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

10.  Antidepressant interactions with the NMDA NR1-1b subunit.

Authors:  Richard Raabe; Lisa Gentile
Journal:  J Biophys       Date:  2008-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.